News

Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis

By: 

Laurie Fickman
Lupus nephritis is one of the most frequent and severe clinical manifestations of lupus, representing a leading cause of morbidity and mortality. Photo courtesy: GettyImages
Lupus nephritis is one of the most frequent and severe clinical manifestations of lupus, representing a leading cause of morbidity and mortality. Photo courtesy: GettyImages
Hugh Roy and Lillie Cranz Cullen Endowed professor of biomedical engineering Chandra Mohan reports that clotting proteins are elevated in the urine of patients with lupus nephritis.
Hugh Roy and Lillie Cranz Cullen Endowed professor of biomedical engineering Chandra Mohan reports that clotting proteins are elevated in the urine of patients with lupus nephritis.

Finding Could Lead to Better Clinical Disease Monitoring

 

University of Houston researcher Chandra Mohan is reporting in Arthritis Research and Therapy that clotting proteins, both those that promote blood clots (pro-thrombotic) and those that work to dissipate them (thrombolytic), are elevated in the urine of patients who suffer from lupus nephritis (LN).

“Among the proteins examined, urine plasmin emerged as the strongest independent predictor of kidney function and renal disease status,” reports Mohan, Hugh Roy and Lillie Cranz Cullen Endowed professor of biomedical engineering at the UH Cullen College of Engineering. “Urine biomarkers represent promising candidates for the early diagnosis as well as the monitoring of disease activity and therapeutic responses in lupus nephritis.” The discovery of the new biomarker for active LN opens the door for clinical monitoring of the disease.

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body attacks its own tissues and organs. Inflammation from the disease can impact many different parts of the body including joints, skin, kidneys, blood cells, brain and heart. Lupus nephritis is one of the most frequent and severe clinical manifestations of SLE, representing a leading cause of morbidity and mortality.

New immunosuppressive drugs and biologics have brought improvements in recent SLE and LN survival rates, but early diagnosis and monitoring disease flares are still challenges that need to be addressed. Renal biopsy remains the gold standard for the diagnosis and prognosis of LN, but it’s invasive and cannot be used for routine monitoring of disease activity and treatment responses. Because of this, several studies focusing on screening and identifying non-invasive biomarkers for the early diagnosis and monitoring of SLE and LN are emerging.

Because coagulation system disorders have been reported in SLE and lupus nephritis patients and the frequency of thrombotic events was documented to be higher in SLE patients than in the general population, Mohan’s lab examined urinary proteins related to coagulation.

Finding elevations in both pro-thrombotic and thrombolytic proteins in the urine of patients with lupus nephritis was unexpected.

“When I first saw the presence of both I thought ‘This can’t be right, so let’s look at this in more detail with more urine samples and better assays,’” said Mohan, who describes the presence of both proteins as “a raging war” within the kidneys. If one or the other predominates, he said, there are medicines that can regulate the clotting in balance, but when both processes are equally upregulated, balancing this biological process becomes clinically challenging.

Urine samples for this study were obtained from 113 patients with LN who had previously been recruited from the renal clinic at UT Southwestern Medical Center between 2007 and 2011. Collaborating with Mohan on the study are lead author, Qing Ling, a practicing nephrologist, Michelle A. Petri, director of the Hopkins Lupus Center at Johns Hopkins Medicine, Baltimore, and Ramesh Saxena, professor of internal medicine –nephology at UT Southwestern Medical Center, Dallas.

Other recent Lupus research conducted by Chandra Mohan:

Researchers Developing Early Detection, Home Monitoring Tests for Lupus Nephritis

Deconstructing Lupus – Could Some of its Makeup Be Part of its Cure?

Faculty: 

Department/Academic Programs: 

Tag: 

Related News Stories

New Technology Could Improve LASIK Surgery, Eye Disease Detection

Dr. Kirill Larin, University of Houston professor of biomedical engineering, is creating new technology to measure the elasticity of the cornea.

UH Professor to Create Ultrafast 3D Clinical Imaging System

LASIK eye surgery – a laser reshaping of the cornea to improve vision – is one of the most popular elective surgeries in the United States, and a University of Houston professor of biomedical engineering intends to improve upon it by giving surgeons more information about the cornea before they begin.  

Nearing a Treatment for Farsightedness

Kirill Larin, professor of biomedical engineering, has received $3 million from the National Eye Institute to create a new technology capable of precise noninvasive and depth-resolved quantitative measurements of the lens mechanical properties in a clinical setting.

UH Professor Developing New Technology to Detect Lens Elasticity

A biomedical researcher at the University of Houston's Cullen College of Engineering is developing new technology that will measure the stiffness of the lens in the eye, which is likely associated with presbyopia, or farsightedness, the inevitable and age-related loss of the ability to focus on nearby objects.